Evidence map›Paper›PMID 37364046›Full record

ArticleGlycobiology2023

Role of the ST6GAL1 sialyltransferase in regulating ovarian cancer cell metabolism.

Robert B Jones, Austin D Silva, Katherine E Ankenbauer, Colleen M Britain, Asmi Chakraborty, Jamelle A Brown, Scott W Ballinger, Susan L Bellis

Open access · bronzeAbstract read
In one paragraph

Article in Glycobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Robert B JonesDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35298, United States.
Austin D SilvaDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35298, United States.
Katherine E AnkenbauerDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35298, United States.
Colleen M BritainDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35298, United States.
Asmi ChakrabortyDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35298, United States.
Jamelle A BrownDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35298, United States.ORCID 0000-0002-2040-0488
Scott W BallingerDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35298, United States.
Susan L BellisDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35298, United States.ORCID 0000-0002-5071-527X
University of Alabama at Birmingham · US

Funding

Training Program in Cell, Molecular, and Developmental BiologyT32GM008111 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YODER, BRADLEY K. · 1985 to 2022
$5.4M
Glycosylation-dependent mechanisms regulating ovarian tumor cell phenotypeR01CA225177 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BELLIS, SUSAN L · 2019 to 2023
$1.6M
NCI NIH HHS R01 CA225177NIGMS NIH HHS T32 GM008111
6 · The paper itself

Abstract

The ST6GAL1 sialyltransferase, which adds α2-6-linked sialic acids to N-glycosylated proteins, is upregulated in many malignancies including ovarian cancer. Through its activity in sialylating select surface receptors, ST6GAL1 modulates intracellular signaling to regulate tumor cell phenotype. ST6GAL1 has previously been shown to act as a survival factor that protects cancer cells from cytotoxic stressors such as hypoxia. In the present study, we investigated a role for ST6GAL1 in tumor cell metabolism. ST6GAL1 was overexpressed (OE) in OV4 ovarian cancer cells, which have low endogenous ST6GAL1, or knocked-down (KD) in ID8 ovarian cancer cells, which have high endogenous ST6GAL1. OV4 and ID8 cells with modulated ST6GAL1 expression were grown under normoxic or hypoxic conditions, and metabolism was assessed using Seahorse technology. Results showed that cells with high ST6GAL1 expression maintained a higher rate of oxidative metabolism than control cells following treatment with the hypoxia mimetic, desferrioxamine (DFO). This enrichment was not due to an increase in mitochondrial number. Glycolytic metabolism was also increased in OV4 and ID8 cells with high ST6GAL1 expression, and these cells displayed greater activity of the glycolytic enzymes, hexokinase and phosphofructokinase. Metabolism maps were generated from the combined Seahorse data, which suggested that ST6GAL1 functions to enhance the overall metabolism of tumor cells. Finally, we determined that OV4 and ID8 cells with high ST6GAL1 expression were more invasive under conditions of hypoxia. Collectively, these results highlight the importance of sialylation in regulating the metabolic phenotype of ovarian cancer cells.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsAntigens, CDbeta-D-Galactoside alpha 2-6-SialyltransferaseFemaleHumansHypoxiaSialyltransferasesSignal TransductionAntigens, CDAntineoplastic Agentsbeta-D-Galactoside alpha 2-6-SialyltransferaseSialyltransferasesST6GAL1 protein, humancancer stem cellshypoxiametabolismsialic acidST6GAL1

Identifiers

PMID37364046
PMCPMC10560082
OpenAlexW4382048583

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.